RE:RE:TSXV:BTI; OTCQB:BIOAF: Neuramedy RC & License Agreement A bit of history:
Neuramedy’s NM-101 (tomaralimab) is a first-in-class humanized IgG4 monoclonal antibody against TLR-2 which was originally developed and termed ‘OPN-305’ by Opsona Therapeutics (Dublin, Ireland) for the treatment of myelodysplastic syndrome in 2015. Neuramedy took over the patent and global rights for tomaralimab from Opsona in 2019 and is now applying it to PD.
from here
and
Irish biotech firm Opsona Therapeutics pops its final pill
Opsona Therapeutics, one of the most heavily backed Irish biotech start-ups, is to be wound up after 14 years in which it raised more than €70m in equity capital.
from here 2019
So seems like tomaralimab failed (commercially at least) for "myelodysplastic syndrome" (a rare bone cancer of some sort) and has been repurposed?
This paper seems to suggest it did work though, "Toll-like receptor 2" is aka "TLR2" I assume, so same receptor in both.
As for the current Neuramedy neurodegenerative work,
try this for some insight:
...
The company is expanding the potential application of tomaralimab to the treatment of Alzheimer’s disease (AD) in conjunction with Amyloid Solution (Seongnam, South Korea) under the name of ‘AS-M801’, considering that TLR-2 is also up-regulated in beta-amyloidopathy like AD and activated by beta-amyloid as in PD and by alpha-synuclein.
Neuramedy is also developing its novel BBB-penetrating antibody (NM-301) for the treatment of neurodegenerative diseases, in collaboration with Aptamer Sciences, a front-runner in Aptamer Technology that will provide antibodies with a BBB shuttle.
So maybe Neuramedy have tried and failed in their own BBB attempts?
Here's hoping. Given that, eventually, the MD&A will probably make it clear how much we got paid up front (not many other receipts to eliminate I assume), a pity they didn't tell us now.
MD